Sestre Milosrdnice University hospital and Institute of Clinical Medical Research
Abstract
Transfusion treatment is administered according to clinical and laboratory results, with ongoing patient assessments. Decisions on necessary measures to prevent any adverse and unexpected events and reactions are made on the basis of hemovigilance and ongoing gathering and analysis of relevant data. Information about transfusion treatment at the Sestre milosrdnice University Hospital Center, Vinogradska site, was retrospectively collected for a period of twelve years (2001-2012). In that period, 14137.25±1693.07 units of all blood products were used, where red blood cells (RBC) accounted for 67.34%, fresh frozen plasma (FFP) for 17.55%, and platelet concentrates (PC) for 14.32%. During the study period, the consumption of RBC was even, of FFP decreased by 45% and of PC increased by 58%. RBC transfusions were received by 10.43% of hospitalized patients, 1.46% of them during surgical procedures. Transfusions of all blood products were received by 14.63% of patients. We found 247 adverse reactions to all blood products. Febrile nonhemolytic and allergic reactions were quite equally represented, 49.5% each. As for other reactions (1%), one transfusion associated circulatory overload and one transfusion related acute lung injury were recorded. There were no fatal post-transfusion reactions.Transfuzijsko liječenje se provodi prema kliničkim i laboratorijskim nalazima uz stalnu procjenu bolesnikova stanja. Nadzorom transfuzijskog liječenja (hemovigilancija) uz kontinuirano prikupljanje i analizu podataka o neželjenim i neočekivanim događajima i reakcijama prosuđuje se o potrebnim mjerama kojima bi se oni spriječili. Retrogradno su prikupljeni podaci o transfuzijskom liječenju bolesnika u KBC Sestre milosrdnice, lokacija Vinogradska, tijekom dvanaest godina (2001.-2012.). Potrošeno je godišnje 14137,25±1693,07 doza svih krvnih pripravaka. Udio eritrokoncentrata (KE) bio je 67,34%, svježe smrznute plazme (SSP) 17,55% i trombokoncentrata (KT) 14,32%. Tijekom promatranog razdoblja potrošnja KE bila je ujednačena, SSP smanjena za 45% i KT povećana za 58%. Transfuzije KE je primilo 10,43% hospitaliziranih bolesnika. Tijekom kirurških zahvata transfuzije KE je primilo 10,11% bolesnika, odnosno 1,46% hospitaliziranih bolesnika. Transfuzije svih krvnih pripravaka primilo je 14,63% bolesnika. U promatranom razdoblju prijavljeno je 247 poslijetransfuzijskih reakcija na sve krvne pripravke. U zbroju svih reakcija podjednako su zastupljene febrilne nehemolitičke i alergijske reakcije (49,5%). Od ostalih (1%) jedna je bila preopterećenje kardiovaskularnog sustava i jedna akutna plućna insuficijencija uzrokovana transfuzijom. Nije bilo poslijetransfuzijskih reakcija sa smrtnim ishodom
